Megestrol acetate in patients with AIDS-related cachexia

Area of Science:

• Clinical Medicine
• Pharmacology
• Infectious Diseases

Background:

• Acquired immunodeficiency syndrome (AIDS) often leads to significant weight loss and anorexia.
• Managing AIDS-related weight loss is crucial for improving patient outcomes and quality of life.

Purpose of the Study:

• To evaluate the efficacy of megestrol acetate in increasing body weight in patients with AIDS-related weight loss.
• To compare the effects of different doses of megestrol acetate against a placebo.

Main Methods:

• A randomized, double-blind, placebo-controlled trial was conducted.
• 270 patients with AIDS-related weight loss were enrolled and randomized to receive placebo or megestrol acetate (100 mg, 400 mg, or 800 mg) daily for 12 weeks.
• Primary efficacy criterion was weight gain, with evaluations at 4-week intervals.

Main Results:

• 64.2% of patients receiving 800 mg/d of megestrol acetate gained 2.27 kg or more, compared to 21.4% receiving placebo (P < 0.001).
• The 800 mg/d dose led to significant improvements in weight gain, lean body mass, appetite, caloric intake, and overall well-being compared to placebo.
• Intent-to-treat analysis confirmed significant weight gain in the 800 mg/d group (62.3%) versus placebo (25%) (P = 0.002).

Conclusions:

• Megestrol acetate is effective in stimulating appetite, increasing food intake, and promoting statistically significant weight gain in patients with AIDS-related weight loss.
• Treatment with megestrol acetate was associated with a patient-reported improvement in overall sense of well-being.
• The 800 mg/d dosage demonstrated the most significant benefits for weight restoration and associated outcomes.